Clinical Trial Update: Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AG-120 (ivosidenib) plus azacitidine vs placebo in previously untreated IDH1-mutated acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AG-120 (ivosidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-23